EyePoint Pharmaceuticals and Ocumension Therapeutics have expanded their license agreements regarding Yutiq and Dexycu in specific Asian markets, according to a press release.
EyePoint received $9.5 million from Ocumension, which will commercialize the products under its own brand names in South Korea and other markets throughout Southeast Asia.
“We are delighted to expand our partnership with Ocumension to include the broader Asian marketplace. The payment from the expanded license agreements will support our operations and the ongoing clinical development of our pipeline, including our
Uncategorized